AzurRx BioPharma Inc. [NASDAQ: AZRX] closed the trading session at $4.43 on 09/14/21. The day’s price range saw the stock hit a low of $4.04, while the highest price level was $6.00. The company report on September 14, 2021 that AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma.
AzurRx BioPharma, Inc. (NASDAQ:AZRX), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, issued a letter to its shareholders from James Sapirstein, President, Chief Executive Officer and Chairman, regarding its recently announced merger with First Wave Bio, Inc. and adoption of the First Wave BioPharma name. The full text of the letter, which has also been posted to the Company’s website, is as follows:.
The stocks have a year to date performance of -54.33 percent and weekly performance of -31.63 percent. The stock has been moved at -73.63 percent over the last six months. The stock has performed -24.95 percent around the most recent 30 days and changed -48.42 percent over the most recent 3-months.
If compared to the average trading volume of 417.57K shares, AZRX reached to a volume of 11611534 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about AzurRx BioPharma Inc. [AZRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AZRX shares is $3.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AZRX stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Dawson James have made an estimate for AzurRx BioPharma Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on January 06, 2021. While these analysts kept the previous recommendation, National Securities raised their target price to Buy. The new note on the price target was released on June 11, 2019, representing the official price target for AzurRx BioPharma Inc. stock. Previously, the target price had yet another raise to $6, while Oppenheimer analysts kept a Outperform rating on AZRX stock.
The Average True Range (ATR) for AzurRx BioPharma Inc. is set at 0.72 The Price to Book ratio for the last quarter was 49.22, with the Price to Cash per share for the same quarter was set at 0.07.
AZRX stock trade performance evaluation
AzurRx BioPharma Inc. [AZRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -31.63. With this latest performance, AZRX shares dropped by -24.95% in over the last four-week period, additionally sinking by -73.63% over the last 6 months – not to mention a drop of -38.47% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AZRX stock in for the last two-week period is set at 33.22, with the RSI for the last a single of trading hit 28.98, and the three-weeks RSI is set at 35.69 for AzurRx BioPharma Inc. [AZRX]. The present Moving Average for the last 50 days of trading for this stock 6.24, while it was recorded at 5.33 for the last single week of trading, and 9.53 for the last 200 days.
AzurRx BioPharma Inc. [AZRX]: An insightful look at the core fundamentals
Return on Total Capital for AZRX is now -1,255.70, given the latest momentum, and Return on Invested Capital for the company is -3,274.23. Return on Equity for this stock declined to -3,305.91, with Return on Assets sitting at -299.37.
Reflecting on the efficiency of the workforce at the company, AzurRx BioPharma Inc. [AZRX] managed to generate an average of -$2,722,622 per employee.AzurRx BioPharma Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.30 and a Current Ratio set at 1.30.
AzurRx BioPharma Inc. [AZRX]: Insider Ownership positions
There are presently around $3 million, or 6.20% of AZRX stock, in the hands of institutional investors. The top three institutional holders of AZRX stocks are: VANGUARD GROUP INC with ownership of 292,409, which is approximately 171.887% of the company’s market cap and around 0.82% of the total institutional ownership; BANK OF NEW YORK MELLON CORP, holding 86,308 shares of the stock with an approximate value of $0.38 million in AZRX stocks shares; and GEODE CAPITAL MANAGEMENT, LLC, currently with $0.19 million in AZRX stock with ownership of nearly 68.933% of the company’s market capitalization.
Positions in AzurRx BioPharma Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 17 institutional holders increased their position in AzurRx BioPharma Inc. [NASDAQ:AZRX] by around 292,786 shares. Additionally, 9 investors decreased positions by around 27,473 shares, while 10 investors held positions by with 258,604 shares. The mentioned changes placed institutional holdings at 578,863 shares, according to the latest SEC report filing. AZRX stock had 6 new institutional investments in for a total of 60,796 shares, while 7 institutional investors sold positions of 25,673 shares during the same period.